Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 233472
The patents relate to Delivery of Opioids through an Inhalation Route.
The technology, the Staccato system, vaporizes excipient-free drugs to form condensation aerosols that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience.
IPSCIO Record ID: 315809
– an exclusive license, with the right to sublicense, to research, develop, import, use, market, sell, have sold, offer for sale and otherwise commercialize the Product in the Field in the U.S., and
– a co-exclusive license, with the right to sublicense, to manufacture and have manufactured the Product for the purposes of researching, developing, importing, using, marketing, selling, having sold, offering for sale and otherwise commercializing the Product in the Field in the U.S.; and,
– a non-exclusive license, with the right to sublicense, solely and to the extent needed to conduct clinical and non-clinical development activities with respect to the Product in the Field outside the U.S.
Product shall mean the drug-device combination product that is comprised of Loxapinc delivered by the Staccato Device, which has been or is during the Term approved by the FDA in the U.S., which form of product is currently designated as AdasuveÂ®.
Staccato Device shall mean any hand-held, fixed-dosage device for the administration of API(s), which relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of API(s) through deep lung inhalation, where the device is known as or based on, but may or may not be referred to, as the StaccatoÂ® system.
The patents relate to the Delivery of antipsychotics through an inhalation route.
IPSCIO Record ID: 291187
– a license under the Licensor Technology to research, develop, import, use, sell, have sold and offer for sale the Product in the Field in the Territory, with such license being exclusive under the Licensor Product Patents and Licensor Know-How and non-exclusive under the Licensor Background Patents.
– a worldwide license under the Licensor Technology to manufacture and have manufactured the Product for use and sale in the Field in the Territory, with such license being co-exclusive with Licensor under the Licensor Product Patents and Licensor Know-How and non-exclusive under the Licensor Background Patents;
– a non-exclusive license solely to conduct clinical and non-clinical development activities with respect to .the Product outside the Territory, solely for the purpose of researching, developing, importing, using, selling, having sold and offering for sale the Product in the Field in the Territory;
For the Trademark and Copyright License, Licensor grants and causes its Affiliates to grant to Licensee, under the Licensor Trademarks and Copyrights an exclusive license to research, develop, manufacture, have manufactured, import, use, sell, have sold and offer for sale Product in the Field in the Territory and a non-exclusive license solely to conduct clinical and non-clinical development activities with respect to the Product outside the Territory, solely for the purpose of researching, developing, importing, using, selling having sold and offering for sale the Product in the Field in the Territory.
Device shall mean any hand-held, single-use, fixed-dosage device for the administration of API( s) which device relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of APl(s) through deep lung inhalation, which device is known as or based on, but may or may not be referred to, as the StaccatoÂ® system.
Loxapine shall mean the compound or any metabolite, salt, polymorphic form, free base form or prodrug form of such compound. Loxapine is for the treatment of psychiatric and/or neurological indications and the symptoms associated therewith, including the rapid treatment of agitation associated with schizophrenia or bipolar disorder. The Product shall be sold in the Territory under the Trademark Adasuveâ„¢
The products will display both trademarks Adasuve and Staccato.
Field shall mean the prevention or treatment of any psychiatric and/or neurological indication and the symptoms associated with these indications.
IPSCIO Record ID: 372509
grants during the Term a non-exclusive, sub-licensable license under the Licensed Technology to, on a Licensed Product-by-Licensed Product basis and effective only with respect to the development of a Licensed Product for a particular indication following Governmental Approval of such Licensed Product for such indication, research and develop such Licensed Product in the Territory.
During the term of this Agreement, Licensor shall not sell any Licensed Product or any Competing Product with respect thereto for use in the Territory, nor grant any right or license to any Third Party with respect to the Licensed Product or any Competing Product in the Territory.
For the Trademarks, Licensor grants an exclusive, sub-licensable license to use the Marks during the Term solely in connection with the promotion, marketing, distribution, offer for sale, and sale of the Licensed Product in the Territory.
The Licensed Product means individually and collectively the BEMA-based product which contains fentanyl as it sole API, is currently the subject of Phase III clinical trials being conducted by Licensor, would, but for the licenses granted under this Agreement, infringe one or more claims of the Licensed Patent Rights, and does not contain naloxone as an additional ingredient. Fentanyl Product means any Licensed Product other than the Naloxone Product.
BEMA(TM) Fentanyl consists of a small, dissolvable, polymer delivery system, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of cheek) membranes. BEMA(TM) Fentanyl has shown in Phase III clinical studies important patient advantages compared to competing products, especially fewer side effects.
BEMATM Fentanyl is a treatment for â€œbreakthroughâ€ cancer pain (i.e., episodes of severe pain which â€œbreak throughâ€ the medication used to control the persistent pain). BDSI believes there is a clear need and growing market for additional narcotic agents in alternative dosage forms to provide rapid pain relief. Fentanyl belongs to the group of medicines called narcotic analgesics, which are used to relieve pain
IPSCIO Record ID: 3004
IPSCIO Record ID: 299286
Products means an AZ-002 Product and/or an AZ-004 Product. Programs means the AZ-002 Program and/or the AZ-004 Program.
AZ-002 Product means a pharmaceutical product in which Alprazolam is the sole active ingredient and it is delivered using Staccato Technology.
AZ-004 Product means a pharmaceutical product in which Loxapine is the sole active ingredient and it is delivered using Staccato Technology.
Alprazolam means alprazolam and all salts, metabolites, prodrug and other physical forms thereof.
Loxapine means loxapine and all salts, metabolites, prodrug and other physical forms thereof.
AZ-002 (Staccato alprazolam). We are developing AZ-002 for the acute treatment of panic attacks associated with panic disorder. In April 2006, we initiated an in-clinic, 36 patient, multi-center, doubleblind, placebo-controlled, proof of concept Phase IIa clinical trial in patients with panic disorder.
AZ-004 (Staccato loxapine). We are developing AZ-004 for the treatment of acute agitation in patients with schizophrenia. In January 2007, we completed enrollment of an in-clinic 120 patient, multi-center, double-blind, placebo-controlled Phase IIa clinical trial in patients with schizophrenia suffering from agitation.
IPSCIO Record ID: 212269
Licensee will be responsible for the manufacturing, distribution, marketing and sales of ONSOLIS in the U.S.
IPSCIO Record ID: 203511
Licensor also grants access to and a right of cross-reference, solely to exercise its rights pursuant to the foregoing license, to the following, in each case to the extent Controlled by Licensor and its Affiliates all Development Data in existence as of the Effective Date; all data related to the formulation or composition of the Product in existence as of or after the Effective Date; and to the extent useful for Licensee or its Sublicensees to develop, make, have made, use, sell, offer to sell, import, export, register, market and promote the Product in the Licensed Field in the Licensed Territory in accordance with Licenseeâ€™s rights under this Agreement, all Preclinical, Non-Clinical and Clinical data, including without limitation pharmacological, pharmacokinetic and toxicological data, [generated with respect to Chronogesic useful in connection with seeking Regulatory Approval for Chronogesic (Chronogesic Data) from trials commenced prior to the Effective Date.
The Product means a transdermal patch for human use using the Licensor Technology containing sufentanil (including all salts thereof) and having a duration of application of (14] days or less, including all dosage strengths thereof and line extensions thereof, and including al] improvements thereto, [together with any adhesive overlay intended for use with such patch.] The term Product includes [any Authorized Generic Product] except as expressly provided herein.
The sufentanil patch, which is in early-stage clinical development employs Licensor's proprietary TRANSDUR(TM) drug-adhesive matrix formulation and is intended to provide relief of moderate-to-severe chronic pain for up to seven (7) days. The product's weeklong duration combined with its reduced size (about 20% of the size of the on-market transdermal fentanyl patches but with a therapeutically equivalent dose) may offer improved patient convenience and compliance.'
Sufentanil is a synthetic opioid analgesic drug approximately 5 to 10 times more potent than its parent drug, fentanyl, and 500 times as potent as morphine.
United States Provisional Patent Application Number 60/621,123 for 'Transdermal Delivery Systems
United States Utility Patent Application Number 10/922,239for 'Implantable Devices and Methods for Treatment of Pain by Delivery of Fentanyl and Fentanyl Congeners
United States Utility Patent Application Number 11/044,521 for 'Devices and Methods for Pain Management'
IPSCIO Record ID: 289191
Product means the Licensed Product, Placebos, and Demonstration Samples.
The Drug Product is BEMA rM Fentanyl, Bucco/ Soluble Film
BEMA means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology Controlled by Licensor.
The Field means the treatment of breakthrough cancer pain in patients tolerant to opioids, the Initial Indication, and, following Governmental Approval in the Territory of the Licensed Product for the Initial Indication, any additional human therapeutic indications for which Governmental Approval is obtained.